Natera, Inc. announced a significant milestone, with over 100 peer-reviewed publications now available on its personalized and tumor-informed molecular residual disease (MRD) test, Signatera. This extensive body of evidence underscores the company's commitment to robust scientific validation.
Multiple validation studies on Signatera have been published in leading scientific journals, including Nature, Nature Medicine, and the Journal of Clinical Oncology. These publications include some of the largest and most comprehensive prospective studies of MRD testing to date.
Signatera is recognized as the most widely used and extensively validated MRD test in the U.S., having supported over 200,000 cancer patients. This scientific leadership is crucial for driving increased adoption among the medical community and securing broader coverage for various cancer types and indications.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.